📊 SRPT Key Takeaways
Is Sarepta Therapeutics, Inc. (SRPT) a Good Investment?
Sarepta demonstrates strong revenue growth (17.9% YoY) and operating margins (49%), but faces critical fundamental challenges with negative gross margins (-4%) and sharply negative operating cash flow (-$202.7M), indicating the company is not converting reported profits into actual cash generation. The combination of negative free cash flow, significant debt ($838.2M), and flat net income growth despite revenue expansion suggests structural profitability issues that are unsustainable.
Why Buy Sarepta Therapeutics, Inc. Stock? SRPT Key Strengths
- Strong revenue growth of 17.9% YoY demonstrating market demand
- Excellent operating margin of 49% and net margin of 45.3%
- Strong liquidity with 4.63x current ratio and $464.4M cash position
SRPT Stock Risks: Sarepta Therapeutics, Inc. Investment Risks
- Negative gross margin (-4%) indicates costs exceed revenue per unit sold - critical structural issue
- Negative operating cash flow of -$202.7M contradicts reported profitability - suggests non-cash gains masking operational losses
- Negative free cash flow (-$204.8M) with $838.2M debt burden is unsustainable without business model changes
- Flat net income growth (0% YoY) despite 17.9% revenue growth indicates deteriorating profitability
Key Metrics to Watch
- Operating cash flow trend - must turn positive to validate business model
- Gross margin improvement - critical to address fundamental cost structure
- Debt management and cash burn rate - monitor covenant compliance and runway
- Net income growth relative to revenue growth - ensure profitability keeps pace with topline expansion
Sarepta Therapeutics, Inc. (SRPT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.63x current ratio provides a solid financial cushion.
SRPT Profit Margin, ROE & Profitability Analysis
SRPT vs Healthcare Sector: How Sarepta Therapeutics, Inc. Compares
How Sarepta Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sarepta Therapeutics, Inc. Stock Overvalued? SRPT Valuation Analysis 2026
Based on fundamental analysis, Sarepta Therapeutics, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sarepta Therapeutics, Inc. Balance Sheet: SRPT Debt, Cash & Liquidity
SRPT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sarepta Therapeutics, Inc.'s revenue has grown significantly by 204% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.80 indicates the company is currently unprofitable.
SRPT Revenue Growth, EPS Growth & YoY Performance
SRPT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $330.5M | $331.0M | $2.88 |
| Q3 2025 | $370.0M | $6.5M | $0.34 |
| Q2 2025 | $360.5M | $6.5M | $0.07 |
| Q1 2025 | $359.5M | $36.1M | $0.37 |
| Q3 2024 | $309.3M | $6.5M | $0.34 |
| Q2 2024 | $239.0M | $6.5M | $0.07 |
| Q1 2024 | $231.5M | $36.1M | $0.37 |
| Q3 2023 | $207.8M | -$23.9M | $-0.46 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sarepta Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SRPT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sarepta Therapeutics, Inc. (CIK: 0000873303)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SRPT
What is the AI rating for SRPT?
Sarepta Therapeutics, Inc. (SRPT) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SRPT's key strengths?
Claude: Strong revenue growth of 17.9% YoY demonstrating market demand. Excellent operating margin of 49% and net margin of 45.3%.
What are the risks of investing in SRPT?
Claude: Negative gross margin (-4%) indicates costs exceed revenue per unit sold - critical structural issue. Negative operating cash flow of -$202.7M contradicts reported profitability - suggests non-cash gains masking operational losses.
What is SRPT's revenue and growth?
Sarepta Therapeutics, Inc. reported revenue of $730.8M.
Does SRPT pay dividends?
Sarepta Therapeutics, Inc. does not currently pay dividends.
Where can I find SRPT SEC filings?
Official SEC filings for Sarepta Therapeutics, Inc. (CIK: 0000873303) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SRPT's EPS?
Sarepta Therapeutics, Inc. has a diluted EPS of $2.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SRPT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Sarepta Therapeutics, Inc. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SRPT stock overvalued or undervalued?
Valuation metrics for SRPT: ROE of 22.0% (sector avg: 15%), net margin of 45.3% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy SRPT stock in 2026?
Our dual AI analysis gives Sarepta Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is SRPT's free cash flow?
Sarepta Therapeutics, Inc.'s operating cash flow is $-202.7M, with capital expenditures of $2.1M. FCF margin is -28.0%.
How does SRPT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 45.3% (avg: 12%), ROE 22.0% (avg: 15%), current ratio 4.63 (avg: 2).